Amgen v Sanofi: Scotus grapples with enablement

The showdown between Amgen and Sanofi concerning the proper test for enablement under Section 112 of the US Patent Act has finally taken place at the US Supreme Court.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Don’t distort enablement law, Amgen tells SCOTUS

9 March 2023 Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand.

Big Pharma

Amgen secures five-year ban on psoriasis drug copycat

20 April 2023 Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.

Big Pharma

Sanofi wins enablement showdown at SCOTUS

18 May 2023 Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies.

More on this story

Big Pharma

Don’t distort enablement law, Amgen tells SCOTUS

9 March 2023 Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand.

Big Pharma

Amgen secures five-year ban on psoriasis drug copycat

20 April 2023 Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.

Big Pharma

Sanofi wins enablement showdown at SCOTUS

More on this story

Big Pharma

Don’t distort enablement law, Amgen tells SCOTUS

9 March 2023 Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand.

Big Pharma

Amgen secures five-year ban on psoriasis drug copycat

20 April 2023 Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.

Big Pharma

Sanofi wins enablement showdown at SCOTUS